Stroke is the second leading cause of mortality and the third leading cause of disability-adjusted life-years worldwide. For each minute of an ischemic stroke, an estimated 1.9 million brain cells die. The year 2015 saw the unprecedented publication of 5 multicentre, randomized, controlled trials. These studies showed that patients with acute ischemic stroke caused by large-vessel thrombus occlusion of the proximal anterior circulation had significantly reduced disability at 90 days when treated with endovascular thrombectomy and usual stroke care compared to usual stroke care alone. As a result, endovascular thrombectomy is now the new North American and European standard of care for suitable patients with acute ischemic stroke caused by large-vessel proximal anterior circulation occlusion. We review key take-home messages in this paradigm shift for radiologists, including the importance of time and workflow efficiency, what currently constitutes appropriate preimaging patient selection and imaging criteria, the use of newer generation thrombectomy devices, safety outcomes, as well as further areas still in need of elucidation.
Stroke is the second leading cause of mortality and the third leading cause of disability-adjusted life-years worldwide [1] . The year 2015 saw the unprecedented publication of 5 multicentre, randomized, controlled trials: the MR CLEAN . These trials showed that patients with acute ischemic stroke caused by large-vessel thrombus occlusion of the proximal anterior circulationdoften poor responders to alteplase therapydhad significantly reduced disability on the modified Rankin Scale (mRS) [7] at 90 days, when treated with rapid endovascular thrombectomy and usual stroke care compared to usual stroke care alone [2e6] . Notably, 3 A meta-analysis of the 5 clinical trials comprising data from 1287 patients (634 with endovascular thrombectomy plus usual stroke care, 653 with usual stroke care alone) showed an astoundingly low number needed to treat (NNT) of 2.6 with endovascular thrombectomy to reduce disability by at least 1 level on the mRS [11] . The NNT to achieve functional independence (defined as mRS 0-2) at 90 days was found to be 5 [11] . The NNTs of 2.6 and 5 for endovascular thrombectomy for acute ischemic stroke, respectively, make it 1 of the most effective treatments in present-day medicine. Thus, endovascular thrombectomy is now the new North American and European standard of care for suitable patients with acute ischemic stroke caused by large-vessel proximal anterior circulation occlusion [12e14].
We review key take-home messages in this paradigm shift for radiologists, including the importance of time and workflow efficiency, what currently constitutes appropriate preimaging patient selection and imaging criteria, the use of newer generation thrombectomy devices, safety outcomes, and further areas still in need of elucidation.
Time Is Brain
For each minute of an ischemic stroke, an estimated 1.9 million brain cells die, and 13.8 billion synapses, as well as 12 km of axonal fibers, are lost [15] . The brain loses as many neurons in 1 hour of an ischemic stroke as it does over the course of 3-6 years of normal aging [15] . Many factors can negatively impact how speedily patients arrive at the hospital following stroke onset, including delayed symptom recognition and even incorrect routing of emergency health services in areas with multiple hospitals where only 1 provides stroke care.
Once patients arrive at the hospital, though, workflow time can be better controlled through the implementation of stroke protocols [16] . The recent clinical trials in 2015 distinguished themselves from past endovascular thrombectomy trials by setting more aggressive workflow targets ( Table 1) . For example, the ESCAPE trial investigators achieved median computed tomography (CT) to groin puncture time and initial CT to reperfusion times of 51 minutes and 84 minutes, respectively [4] . In comparison, the IMS III trialdwhich showed futility for endovascular thrombectomydtargeted a less stringent groin puncture time of 5 hours from stroke onset, or roughly 2 hours after hospital presentation [10] .
Preimaging Patient Selection

Time From Stroke Onset
With the earlier IMS III trial, patients needed to have started alteplase within 3 hours of stroke onset in order to be eligible for randomization [10] . In practice, patients do not always present promptly to hospital after stroke onset, as discussed above. The trials in 2015 attempted to expand this recruitment window to broaden clinical applicability. The REVASCAT and ESCAPE trials included patients randomized up to 8 and 12 hours, respectively, after symptom onset. However, the numbers of patients presenting after 6 hours from symptom onset were small in these trials, resulting in inadequate power to assess endovascular therapy in this subgroup [4, 6] . The meta-analysis showed a common odds ratio (cOR) of 2.66 (95% confidence interval [CI]: 1.83-3.87) in favor of intervention resulting in lower mRS scores at 90 days for patients randomized up to 5 hours after symptom onset, and cOR of 1.76 (95% CI: 1.05-2.97) for patients randomized greater than 5 hours [11] . However, there was no significant benefit on functional independence (defined as mRS 0-2) in the latter group. Thus, endovascular thrombectomy appears to benefit patients randomized 5-7 hours after symptom onset, but definitive proof of benefit in patients randomized greater than 6 hours remains to be established by ongoing trials [11] . As it stands, the commonly accepted cut-off time from symptom onset to endovascular thrombectomy consideration is 6 hours.
Age and Sex
The IMS III trial initially showed directions of effect favoring endovascular thrombectomy for men and alteplase alone for women, although neither effect was statistically significant [10] . The meta-analysis showed similar effect sizes for both genders in favor of endovascular thrombectomy reducing mRS scores at 90 days (Table 1 ) [11] .
The meta-analysis showed a direction of effect favoring endovascular thrombectomy in patients 18-49 years of age, although the cOR of 1.36 was not significant (95% CI: 0.75-2.46). Patients 50-59, 60-69, and 70-79 years of age had significant cORs of 2.85 (95% CI: 1.72-4.72), 2.58 (95% CI: 1.49-4.48), and 2.41 (95% CI: 1.55-3.74), respectively. The greatest effect was actually seen in patients older than 80 years of age (cOR 3.68, 95% CI: 1.95-6.92). There is no reason to withhold endovascular thrombectomy from a patient based on age alone, although bearing in mind that older age is positively correlated with higher mRS scores at 90 days [11] . Premorbid conditions and personal wishes of the patient and family are important considerations for making decisions in this age group.
Baseline Stroke Severity
Baseline stroke severity on hospital presentation is usually assessed using the National Institutes of Health Stroke Scale (NIHSS). In the meta-analysis, NIHSS scores 11 had corresponding cORs that were significant and ranged from 2.52-2.81 in favor of endovascular thrombectomy reducing mRS scores at 90 days [11] . For NIHSS scores 10 corresponding to minor strokes, the direction of effect favored endovascular thrombectomy, but the cOR of 1.67 was not significant (95% CI: 0.80-3.50) [11] . Thus, patients with minor strokes confirmed to have large-vessel proximal anterior circulation occlusion should be treated on a case-by-case basis, taking into account patient preferences. However, it should be noted that large-vessel proximal anterior circulation occlusions often respond poorly to optimal medical therapy alone with alteplase [17] .
Eligibility for Intravenous Alteplase
Effect sizes are similar for alteplase-treated patients (cOR: 2.45; 95% CI: 1.68-3.57) and alteplase-ineligible patients (cOR: 2.43; 95% CI: 1.30-4.55) who subsequently undergo endovascular thrombectomy compared to usual stroke care alone [11] . Thus, eligibility for endovascular thrombectomy should be assessed regardless of whether a patient is eligible for intravenous alteplase.
Appropriate Imaging and Imaging Selection Criteria
Noncontrast CT Head and Alberta Stroke Program Early CT Score North American and European stroke guidelines recommend noncontrast CT head as the initial imaging test due to widespread availability, low cost, and imaging speed [12e 14]. First, if the stroke is hemorrhagic in etiology, then neither alteplase nor endovascular thrombectomy is warranted. Second, early ischemic changesdhyperdense middle cerebral artery (MCA) sign, loss of basal ganglia definition, insular ribbon sign, loss of grey-white matter differentiation with or without sulcal effacement, or focal parenchymal hypodensitydmay be present ( Figures 1D, 1E , 2D, 2E, 3D, and 3E). Third, noncontrast CT head plays a role in the assessment of alteplase eligibility.
The Alberta Stroke Program Early CT Score (ASPECTS)da 10-point quantitative, topographic CT scoredis used to assess the extent of early ischemic change. Lower ASPECTS scores indicate more extensive and irreversible early ischemic changes ( Figures 1D, 1E , 2D, 2E, 3D, and 3E) [18, 19] . The meta-analysis showed significant cORs of 2.34 (95% CI: 1.68-3.26) for ASPECTS 6-8 and 2.66 (95% CI: 1.61-4.40) for ASPECTS 9-10 in favor of decreased mRS scores at 90 days with endovascular thrombectomy [11] . Although the direction of effect was in favor of endovascular thrombectomy for ASPECTS 5, the cOR of 1.24 was not significant (95% CI: 0.62-2.49). However, as most of the 5 clinical trials excluded patients with ASPECTS 5, further studies are still needed to further elucidate the true effect size in this subgroup [11] .
CT Angiography: Intracranial Occlusion Location
North American and European stroke guidelines recommend CT angiographydpreferably multiphase to avoid incorrect collateral assessment secondary to acquiring images too early in the arterial phasedof the intracranial and neck vasculature as the next imaging test for thrombus localization and collateral scoring, the latter to improve the accuracy of assessing early ischemic changes ( Figures 1A, 1B, 1C , 2A, 2B, 2C, 3A, 3B, and 3C) [12e14]. In the meta-analysis, 69% and 21% of occlusions occurred at the M1 segment of the middle cerebral artery and in the internal carotid artery, respectively [11] . Notably, 8% of occlusions occurred at the M2 segment with a direction of effect in favor of endovascular thrombectomy (cOR: 1.28; 95% CI: 0.51-3.21). However, as most of the 5 clinical trials restricted enrolment to more proximal occlusions, the meta-analysis was subsequently underpowered to fully assess the subgroup with M2 occlusion. As it stands, endovascular thrombectomy is currently recommended for proximal anterior circulation (internal carotid artery and M1) occlusions.
Patients with a proximal anterior circulation occlusion and concomitant occlusion of the extracranial internal carotid artery had a cOR of 2.95 (95% CI: 1.38-6.32), favoring endovascular thrombectomy reducing mRS scores at 90 days, although there was no significant benefit on functional independence (mRS 0-2) [11] . Due to the heterogeneity of concomitant lesion treatment (no revascularization of concomitant lesion vs stenting vs angioplasty) across the 5 clinical trials, optimal treatment approach for these concomitant occlusions remains to be determined.
CT Perfusion
Of the 5 clinical trials, only the EXTEND IA trial employed CT perfusion consistently prior to randomization to exclude patients with large ischemic cores and no clinically significant salvageable ischemic penumbrae, on the basis of low likelihood of good outcome and high risk of symptomatic hemorrhage [3] . The SWIFT PRIME trial included CT perfusion imaging to identify patients with salvageable tissue at its beginning but modified the study protocol to make it optional [5] . The SWIFT PRIME trial investigators subsequently assessed the subgroup of patients who received baseline perfusion imaging and found that, among 70 patients who had >90% reperfusion with either endovascular thrombectomy and alteplase or alteplase alone, baseline ischemic core volumes predicted 27-hour infarct volumes, with a median difference of 8 mL (32 mL for patients with hemorrhagic transformation). Furthermore, in 12 patients with <10% reperfusion, baseline ischemic penumbra volumes correlated with 27-hour infarct volumes (r ¼ 0.78, P ¼ .005), with a median difference of 39 mL [20] .
Although CT perfusion was not part of the formal imaging selection criteria for the MR CLEAN trial, it was nonetheless performed in approximately 65% of patients prior to randomization. MR CLEAN investigators subsequently showed that, per 10 mL of ischemic core volume and penumbra volume, the odds ratios for a shift towards better outcome on the mRS were 0.79 (95% CI: 0.73-0.87) and 0.97 (95% CI: 0.92-1.01), respectively, signifying that larger ischemic core and penumbra volumes were associated with worse functional outcomes. Notably, regardless of whether the ischemic core volume was <70 mL or 70 mL, there was a shift towards better functional outcome after endovascular thrombectomy compared to usual stroke care alone. Thus, although perfusion parameters are useful for predicting functional outcome, the data cannot reliably predict who should be excluded from endovascular thrombectomy due to futility [21] .
In our experience, cerebral blood volume on CT perfusion can reliably predict the infarct volume on 24-hour CT scan (Figures 1E, 2E, and 3E ) and is very helpful in patient selection for endovascular thrombectomy [22] . A variety of challenges exist with the use of CT perfusion, including susceptibility to patient motion (z-axis motion), limited brain coverage, the setting of an appropriate blood flow threshold, and the amount of time required to acquire, process, and interpret images [23, 24] . Recognizing the controversial role of CT perfusion in thrombectomy selection, current North American and European guidelines do not make a firm recommendation for CT perfusion, and instead leave perfusion imaging up to clinical discretion [12e14].
Magnetic Resonance and Magnetic Resonance Angiography
A relatively short, 6-minute magnetic resonance (MR) protocol has been described for acute ischemic stroke, allowing MR to fit into the stringent acute stroke workflow [25]. A study of 55 patients with acute proximal anterior circulation occlusions found that CT perfusion had poorer contrast-to-noise ratios and, as a result, larger measurement errors compared to diffusion-weighted MR performed at around the same time [24] .
However, the practical drawbacks of MR are numerous. In most stroke centres, MR is simply not availabledeither promptly or at alldaround the clock. Attempting to screen a possibly obtunded stroke patient for metallic implants can be immensely challenging. The closed structure of an MR scanner compared to a CT scanner makes it more difficult to monitor patients during scans. MR is also very susceptible to patient motion [26] . Current North American and European guidelines leave MR imaging up to clinical discretion [12e14].
Current Thrombectomy Techniques
There are no trials that compare different thrombectomy tools. Most of the recent trials showing endovascular thrombectomy benefit have used stent retrievers [2e6]. Notably, stent retrievers were used in only a minority of patients in the IMS III study, which showed endovascular thrombectomy futility [10] . Other thrombectomy devices have yet to be tested in a clinical trial setting.
Safety Outcomes
The meta-analysis assessed safety outcomes [11] . The incidence of symptomatic intracranial hemorrhage was marginally greater in the intervention population (4.4%) compared to the control population (4.3%). However, both parenchymal hematoma type 2 (occupying >30% of the infarct territory with mass effect within 5 days of treatment) and mortality at 90 days occurred less frequently in the intervention population (5.1% and 15.3%, respectively) compared to the control population (5.3% and 18.9%, respectively). Thus, endovascular thrombectomy is a safe alternative to medical therapy alone.
Further Areas for Research
While the recent clinical trials and meta-analysis have markedly propelled stroke therapy forward, there remain areas of uncertainty in need of elucidation from future clinical trials. These include patients presenting >5 hours from stroke onset, patients with ASPECTS 5 (extensive early ischemic change), whether to use general anesthesia or sedation as the primary approach, occlusions of the distal anterior circulation and posterior circulation, and the optimal treatment approach for concomitant occlusions of the proximal extracranial internal carotid artery. 
Conclusion
Endovascular thrombectomy is now the new standard of care for suitable patients with acute ischemic stroke caused by large-vessel proximal anterior circulation occlusion. This represents a paradigm shift for radiologists with emphasis on the importance of time and workflow efficiency.
